217 related articles for article (PubMed ID: 16804806)
1. [Polypharmacy in the treatment of schizophrenia].
Messer T; Tiltscher C; Schmauss M
Fortschr Neurol Psychiatr; 2006 Jul; 74(7):377-91. PubMed ID: 16804806
[TBL] [Abstract][Full Text] [Related]
2. Polypharmacy in schizophrenia.
Zink M; Englisch S; Meyer-Lindenberg A
Curr Opin Psychiatry; 2010 Mar; 23(2):103-11. PubMed ID: 20051861
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic polypharmacy in patients with schizophrenia in a brief hospitalization unit.
Lerma-Carrillo I; de Pablo Brühlmann S; del Pozo ML; Pascual-Pinazo F; Molina JD; Baca-García E
Clin Neuropharmacol; 2008; 31(6):319-32. PubMed ID: 19050409
[TBL] [Abstract][Full Text] [Related]
4. Combined treatment with amisulpride in patients with schizophrenia discharged from a short-term hospitalization unit: a 1-year retrospective study.
Molina JD; Lerma-Carrillo I; Leonor M; Pascual F; Blasco-Fontecilla H; González-Parra S; López-Muñoz F; Alamo C
Clin Neuropharmacol; 2009; 32(1):10-5. PubMed ID: 18978498
[TBL] [Abstract][Full Text] [Related]
5. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
[TBL] [Abstract][Full Text] [Related]
6. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
7. Polypharmacy with second-generation antipsychotics: a review of evidence.
Pandurangi AK; Dalkilic A
J Psychiatr Pract; 2008 Nov; 14(6):345-67. PubMed ID: 19057237
[TBL] [Abstract][Full Text] [Related]
8. Prescription profiles for pharmacological treatment of Japanese inpatients with schizophrenia: comparison between 2007 and 2009.
Yoshio T; Inada T; Uno J; Miwa T; Kitagawa K; Miyahara Y; Umeda K; Kato T; Inagaki A; Nabeshima T
Hum Psychopharmacol; 2012 Jan; 27(1):70-5. PubMed ID: 22249957
[TBL] [Abstract][Full Text] [Related]
9. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
10. A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia.
Suzuki T; Uchida H; Watanabe K; Yagi G; Kashima H
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):361-9. PubMed ID: 14751434
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic polypharmacy or monotherapy?
Gardos G
Neuropsychopharmacol Hung; 2005 Jun; 7(2):72-7. PubMed ID: 16167458
[TBL] [Abstract][Full Text] [Related]
13. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
[TBL] [Abstract][Full Text] [Related]
14. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison.
Roh D; Chang JG; Kim CH; Cho HS; An SK; Jung YC
Aust N Z J Psychiatry; 2014 Jan; 48(1):52-60. PubMed ID: 23671214
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive treatment with risperidone in clozapine-resistant schizophrenia: a case report and review.
Lerma-Carrillo I; Molina JD; Cuevas-Durán T; González-Parra S; Blasco-Fontecilla H; Andrade-Rosa C; López-Muñoz F; Alamo C
Clin Neuropharmacol; 2007; 30(2):114-21. PubMed ID: 17414944
[TBL] [Abstract][Full Text] [Related]
16. Polypharmacy in psychiatry: a multi-state comparison of psychotropic drug combinations.
Sheppard C; Beyel V; Fracchia J; Merlis S
Dis Nerv Syst; 1974 Apr; 35(4):183-9. PubMed ID: 17894114
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy in the treatment of schizophrenia.
Wolff-Menzler C; Hasan A; Malchow B; Falkai P; Wobrock T
Pharmacopsychiatry; 2010 Jun; 43(4):122-9. PubMed ID: 20309809
[TBL] [Abstract][Full Text] [Related]
18. Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia.
Xiang YT; Weng YZ; Leung CM; Tang WK; Ungvari GS
Pharmacopsychiatry; 2007 Mar; 40(2):47-52. PubMed ID: 17447172
[TBL] [Abstract][Full Text] [Related]
19. [Are mood stabilizers beneficial in the treatment of schizophrenia?].
Berle JØ; Spigset O
Tidsskr Nor Laegeforen; 2005 Jun; 125(13):1809-12. PubMed ID: 16012547
[TBL] [Abstract][Full Text] [Related]
20. A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in taiwan.
Gau SS; Chung CH; Gau CS
J Clin Psychopharmacol; 2008 Jun; 28(3):271-8. PubMed ID: 18480683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
